CANESTEN ® Clotrimazole

CANESTEN ® is a drug based on Clotrimazole

THERAPEUTIC GROUP: Antimycotics for topical use - imidazole derivatives

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications CANESTEN ® Clotrimazole

CANESTEN ® is indicated for the treatment of cutaneous mycoses and skin folds sustained by microorganisms sensitive to Clotrimazole.

The cutaneous powder form is useful in the topical treatment of cutaneous mycoses and skin folds in particularly damp or poorly ventilated regions.

Mechanism of action CANESTEN ® Clotrimazole

The topical use of CANESTEN ® allows Clotrimazole to carry out its therapeutic activity on site with very high efficacy, minimizing the potential side effects associated with the systemic absorption of the drug.

As an imidazole derivative, Clotrimazole has an anti-fungal action against numerous fungal species - including those belonging to the genera Candida, Blastomyces, Histoplasma, Coccidioides and dermatophytes - by inhibiting the? Enzyme 14-alpha-sterol dimethylase, which is fundamental for the biosynthesis of ? ™ ergosterol, an essential component of cytoplasmic membrane of fungi.

The accumulation of 14 alpha methyl sterols also causes a subversion of the membrane phospholipid structure with consequent impairment of the functionality of the various membrane enzymes, which results in an inhibition of the growth of the fungus.

Different studies have also demonstrated the antimicrobial chemotherapy activity of Clotrimazole also towards Trichomonas vaginalis, Gram-positive bacteria, Gram-negative bacteria, molds and yeasts, thus resulting in a drug of first choice in the treatment of such infections, also considering the low risk of onset of resistance mechanisms.

Studies carried out and clinical efficacy

THE EFFECTIVENESS OF THE CLOTRIMAZOLE IN THE TREATMENT OF VERSICOLOR PYTHRIASIS

J Dermatol. 2010 Aug; 37 (8): 699-702.

Randomized clinical trial demonstrating the greater efficacy of Clotrimazole in cream compared to Fluconazole taken orally in the control of skin diseases such as pityriasis versicolor.

NEW CLOTRIMAZOLO RELEASE SYSTEMS

AAPS PharmSciTech. 2011 Mar; 12 (1): 239-47.

New formulation that combines? ™ jojoba oil with Clotrimazole, able to optimize drug release significantly improving its antifungal activity thanks to the higher degree of chemical and physical stability.

THE CLOTRIMAZOLO AS A RADIOSENSIBILIZER

Anticancer Drugs. 2010 Oct; 21 (9): 841-9.

Experimental study conducted on laboratory animals that demonstrates how Clotrimazole can have a sensitizing action for the radiotherapy of tumors, improving their efficacy and the related result.

Method of use and dosage

CANESTEN ®

? 1% Clotrmiazole cream;

? 1% dermal powder of Clotrimazole;

? 1% Clotrimazole solution for dermal spray.

The therapeutic scheme and the type of formulation to be used varies according to the body regions to be treated.

More precisely :

CANESTEN ® in cream, to be applied in small quantities 2-3 times a day on the affected region by rubbing it slightly, is indicated for the treatment of cutaneous areas without hair.

CANESTEN ® in spray instead, to be sprayed on the region affected by mycosis 2 times a day, is useful in treating regions with hair or particularly large.

CANESTEN ® in skin powder to be applied 2-3 times a day, after having thoroughly cleansed and dried the area, is useful in the treatment of damp or difficult to aerate skin areas such as the foot.

In all cases it is advisable to prolong the therapy for at least two weeks after the disappearance of the clinical signs of disease.

Warnings CANESTEN ® Clotrimazole

Before starting the use of CANESTEN ® it would be advisable to consult your doctor to characterize the pathology in place and the possible prescription appropriateness.

The use of this drug, especially when prolonged for particularly long periods or for particularly large areas, could expose the patient to the risk of allergic reactions.

It is recommended to avoid the application of CANESTEN ® on skin areas with obvious lesions or on mucous membranes rather than in the eyes.

The cream form contains cetostearyl aclool, potentially responsible for contact dermatitis in atopic patients.

PREGNANCY AND BREASTFEEDING

The absence of clinical trials able to fully characterize the safety profile of the drug for fetal health considerably limits the use of CANESTEN ® during pregnancy and in the subsequent period of breastfeeding.